Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer. ADMET and DMPK, [S. l.], v. 4, n. 4, p. 314–326, 2016. DOI: 10.5599/admet.4.4.341. Disponível em: https://pub.iapchem.org/ojs/index.php/admet/article/view/341. Acesso em: 30 oct. 2025.